Question
Immunofluorescence.
Q8 2 marks Short Notes ★ ✓
Answer
Immunofluorescence is a laboratory technique that uses fluorescent-dye-labelled antibodies to detect and visualize a specific antigen (or antibody) in a sample under a fluorescence microscope, exploiting the specificity of antigen-antibody binding combined with the visual sensitivity of fluorescence.
Principle : a fluorochrome (fluorescent dye, e.g., fluorescein isothiocyanate, FITC — emits green fluorescence; or rhodamine — emits red) is chemically conjugated to an antibody without destroying its antigen-binding specificity; when this labelled antibody binds its target antigen in a sample, the resulting complex fluoresces (glows) under ultraviolet/blue light exposure in a fluorescence microscope, allowing direct visualization and localization of the antigen.
Types :
Direct immunofluorescence (DIF) — a fluorochrome-labelled antibody is applied directly to the sample and binds its specific antigen in a single step; simple and rapid, but requires a separately labelled antibody for each different target antigen, limiting flexibility.
Indirect immunofluorescence (IIF) — an unlabelled primary antibody (specific for the target antigen) is applied first, followed by a fluorochrome-labelled secondary antibody (directed against the species/class of the primary antibody, e.g., anti-human IgG); this amplifies the signal (multiple labelled secondary antibodies can bind each primary antibody, increasing sensitivity) and allows the same labelled secondary antibody to be used with many different unlabelled primary antibodies, making it more versatile and widely used.
Applications :
Rapid identification of microorganisms directly in clinical specimens (e.g., direct fluorescent antibody test for rabies virus antigen in brain tissue, Chlamydia trachomatis in genital/conjunctival smears, Bordetella pertussis in nasopharyngeal secretions, Legionella in respiratory specimens).
Detection of circulating autoantibodies (e.g., antinuclear antibody testing in SLE, using patient serum as the “primary antibody” against a fixed cell substrate, detected by fluorochrome-labelled anti-human immunoglobulin — an indirect immunofluorescence format).
Confirmatory serological testing (e.g., FTA-ABS test for syphilis).
Immunohistochemistry/immunopathology, localizing immune complex deposition in tissue biopsies (e.g., renal biopsy in glomerulonephritis).
1 General Properties of Viruses and Virus Host Interaction
Other Years Asked
1 A 40-year-old diabetic man came to medicine O.P with fever, shortness of breath. His
family members also give history of fever and sore throat. His oxygen saturation was low
and chest x-ray showed diffuse infiltration
( 2022 July (Supplementary) (2019 Scheme) Essay · 11 marks 2 A 20-year-old female with history of multiple blood transfusions presents to outpatient
department with fever, malaise, nausea vomiting and yellowish discoloration of urine.
The blood examination showed elevated bilirubin and liver enzymes and positive for
HBs Ag 2024 March (Supplementary) (2019 Scheme) Essay · 10 marks 3 A 40-year-old previously healthy adult, presented to the medicine outpatient department with
malaise, fatigue, low grade fever, nausea and aversion to food. She complains of itching all over
the body. She provides history of multiple blood transfusions following a road traffic accident
eight months ago. The anti HBc IgM was positive. AST and ALT (Liver enzyme 2025 March (Supplementary (SAY)) (2019 Scheme) Essay · 10 marks 4 Classify immunity. Add a note on passive immunity. 2023 July (Supplementary) (2019 Scheme) Short Essay · 8 marks 5 Explain the reasons that helped successful eradication of smallpox. 2022 February (2019 Scheme) Short Essay · 8 marks 6 List molecular methods used in laboratory diagnosis of infections. Briefly mention
principle of each method. Discuss advantages and disadvantages of each method.
(1+3+2+2) 2024 June (Supplementary) (2019 Scheme) Short Essay · 8 marks 7 Discuss applications of monoclonal antibodies. 2024 June (Supplementary) (2019 Scheme) Short Essay · 8 marks 8 What is virulence. List the different mechanisms of virulence in bacteria. Explain one of them in detail.
(1+ 3+2) 2024 December (Supplementary) (2019 Scheme) Short Essay · 6 marks 9 Classify immunity. Describe acquired immunity with examples (2+4) 2025 March (Supplementary (SAY)) (2019 Scheme) Short Essay · 6 marks 10 Define pandemic. Name any four pandemics. Describe in detail strategies taken for their control. (1+2+3) 2024 December (Supplementary) (2019 Scheme) Short Essay · 6 marks 11 Enumerate four common etiological agents for viral hemorrhagic fever. Describe the laboratory diagnosis
for any one of them. 2025 March (Supplementary (SAY)) (2019 Scheme) Short Essay · 6 marks 12 Discuss the laboratory diagnosis of hepatitis B virus Infection 2014 September (Supplementary) (2010 Scheme) Short Essay · 5 marks 13 Markers of hepatitis B virus and lab. diagnosis of hepatitis B infection. 2019 July (Supplementary) (2010 Scheme) Short Essay · 5 marks 14 Active immunity. 2017 February (2010 Scheme) Short Essay · 5 marks 15 General characters of viruses 2017 February (2010 Scheme) Short Essay · 5 marks 16 Monoclonal antibodies and its application in clinical microbiology 2014 September (Supplementary) (2010 Scheme) Short Essay · 5 marks 17 Monoclonal antibodies. 2021 December (Supplementary) (2010 Scheme) Short Essay · 5 marks 18 Describe immunoglobulin G (IgG) 2017 August (Supplementary) (2010 Scheme) Short Essay · 5 marks 19 Compare and contrast active and passive immunity. 2020 February (Supplementary) (2010 Scheme) Short Essay · 5 marks 20 Monoclonal antibody and its application 2025 March (Supplementary) (2010 Scheme) Short Essay · 5 marks 21 Immunoglobulin G (IgG) 2018 July (Supplementary) (2010 Scheme) Short Essay · 5 marks 22 Tzanck smear. 2022 February (2019 Scheme) Short Answer · 4 marks 23 Secondary immune response 2024 June (Supplementary) (2019 Scheme) Short Answer · 4 marks 24 Vaccine against Varicella zoster virus. 2022 February (2019 Scheme) Short Answer · 4 marks 25 PCR – Principle 2022 July (Supplementary) (2019 Scheme) Short Answer · 4 marks 26 What are the laboratory tests available to detect Hepatitis C in a suspected patient 2024 June (Supplementary) (2019 Scheme) Short Answer · 4 marks 27 Respiratory Syncytial virus. 2023 January (Supplementary) (2019 Scheme) Short Answer · 4 marks 28 Write the applications of ELISA test 2024 March (Supplementary) (2019 Scheme) Short Answer · 4 marks 29 Modes of transmission and laboratory diagnosis of Monkey pox (M Pox) 2024 December (Supplementary) (2019 Scheme) Short Answer · 4 marks 30 Draw the structure of HIV and label. Add a note on its transmission (2.5+1.5) 2022 February (2019 Scheme) Short Answer · 4 marks 31 Human papilloma virus and the role of vaccines 2025 March (Supplementary (SAY)) (2019 Scheme) Short Answer · 3 marks 32 Coagulase test 2014 March (2010 Scheme) Short Note · 2 marks 33 Adjuvant. 2023 March (Supplementary) (2010 Scheme) Short Note · 2 marks 34 Coxsackie viruses. 2013 September (Supplementary) (2010 Scheme) Short Note · 2 marks 35 Give two examples of antiviral drugs. 2019 February (2010 Scheme) Short Note · 2 marks 36 Adjuvant 2019 July (Supplementary) (2010 Scheme) Short Note · 2 marks 37 Papilloma virus 2014 September (Supplementary) (2010 Scheme) Short Note · 2 marks 38 Prions 2013 September (Supplementary) (2010 Scheme) Short Note · 2 marks 39 Eclipse phase in viral replication. 2014 March (2010 Scheme) Short Note · 2 marks 40 Polio vaccines 2024 August (Supplementary) (2010 Scheme) Short Note · 2 marks 41 Monoclonal antibodies and its TWO applications 2024 August (Supplementary) (2010 Scheme) Short Note · 2 marks 42 Pulse polio programme. 2022 May (Supplementary) (2010 Scheme) Short Note · 2 marks 43 Continuous cell lines 2015 February (2010 Scheme) Short Note · 2 marks 44 Human papilloma virus 2024 March (Supplementary) (2010 Scheme) Short Note · 2 marks 45 Active immunity. 2013 September (Supplementary) (2010 Scheme) Short Note · 2 marks 46 Cytopathic effect (CPE) 2013 September (Supplementary) (2010 Scheme) Short Note · 2 marks 47 Hepatitis B vaccine 2021 December (Supplementary) (2010 Scheme) Short Note · 2 marks 48 Significance of p24 antigen. 2014 March (2010 Scheme) Short Note · 2 marks 49 Hereditary angioneurotic edema 2015 February (2010 Scheme) Short Note · 2 marks 50 Primary cell culture 2021 May (Supplementary) (2010 Scheme) Short Note · 2 marks 51 Natural passive immunity 2022 October (Supplementary) (2010 Scheme) Short Note · 2 marks 52 Opportunistic viral infections in AIDS patients. 2022 October (Supplementary) (2010 Scheme) Short Note · 2 marks 53 Virus cultivation by cell culture method. 2016 October (Supplementary) (2010 Scheme) Short Note · 2 marks 54 Secretory IgA 2014 September (Supplementary) (2010 Scheme) Short Note · 2 marks 55 Gamma interferon. 2013 September (Supplementary) (2010 Scheme) Short Note · 2 marks 56 Koch’s postulates. 2020 February (Supplementary) (2010 Scheme) Short Note · 2 marks 57 Clinical significance of IgM 2025 March (Supplementary) (2010 Scheme) Short Note · 2 marks 58 Tissue culture 2016 February (2010 Scheme) Short Note · 2 marks 59 Aseptic meningitis 2017 February (2010 Scheme) Short Note · 2 marks 60 Adjuvants 2016 October (Supplementary) (2010 Scheme) Short Note · 2 marks 61 MMR vaccine. 2013 April (2010 Scheme) Short Note · 2 marks 62 IgA 2018 February (2010 Scheme) Short Note · 2 marks 63 Elusion 2020 February (Supplementary) (2010 Scheme) Short Note · 2 marks 64 Pulse polio programme 2020 February (Supplementary) (2010 Scheme) Short Note · 2 marks 65 Gamma interferon. 2022 October (Supplementary) (2010 Scheme) Short Note · 2 marks 66 Gene therapy 2015 September (Supplementary) (2010 Scheme) Short Note · 2 marks 67 Incubation period. 2023 July (Supplementary) (2010 Scheme) Short Note · 2 marks 68 Name two acute inflammatory markers. 2023 March (Supplementary) (2010 Scheme) Short Note · 2 marks 69 Window period in HIV infection 2021 February (Supplementary) (2010 Scheme) Short Note · 2 marks 70 Cell cultures for growing viruses 2015 September (Supplementary) (2010 Scheme) Short Note · 2 marks 71 Tissue cell line culture 2018 July (Supplementary) (2010 Scheme) Short Note · 2 marks 72 Morphology of bacteriophage 2013 September (Supplementary) (2010 Scheme) Short Note · 2 marks 73 Which of the following can be used to cultivate viruses 2024 December (Supplementary) (2019 Scheme) MCQ · 1 mark 74 Regarding the laboratory diagnosis of HIV infection 2025 March (Supplementary (SAY)) (2019 Scheme) MCQ · 1 mark 75 A: B lymphocytes have immunological memory.
R: Helper T lymphocytes help B lymphocytes make antibodies 2024 December (Supplementary) (2019 Scheme) MCQ · 1 mark 76 Name four contributions of Louis Pasteur 2023 July (Supplementary) (2019 Scheme) 1 mark 77 Hand foot and mouth disease is NOT caused by 2024 December (Supplementary) (2019 Scheme) MCQ · 1 mark 78 Define acute phase reactants. Give one example. 2024 June (Supplementary) (2019 Scheme) 1 mark 79 Western blot test for HIV 2024 December (Supplementary) (2019 Scheme) MCQ · 1 mark 80 Name any two viruses causing diarrhoeal disease 2022 July (Supplementary) (2019 Scheme) 1 mark 81 A: Window period in HIV infection is from entry of virus to appearance of symptoms.
R: Guidelines for HIV testing in India have been laid down by National AIDS Control Organisation. 2024 December (Supplementary) (2019 Scheme) MCQ · 1 mark 82 What is the likely clinical diagnosis 2024 December (Supplementary) (2019 Scheme) MCQ · 1 mark 83 Name TWO tests used for diagnosis of HIV infection in window period. 2024 March (Supplementary) (2019 Scheme) 1 mark 84 The protein which acts as virulence factor is the 2024 December (Supplementary) (2019 Scheme) MCQ · 1 mark 85 What is the role of memory cells in immune response. 2023 January (Supplementary) (2019 Scheme) 1 mark